Beatcc Archives

Immunotherapy added to first-line standard therapy significantly improves survival in metastatic or recurrent cervical cancer

Published in The Lancet, results of the randomized phase III BEATcc academic trial (ENGOT-Cx10/GEICO 68-C/JGOG1084/GOG-3030) show that adding immune checkpoint…